Xiangyuan Wu, MD

Titles

Professor and Director of Oncology Department of the Third Affiliated Hospital of Sun Yat-Sen University

Vice Director of Internal Medicine of the Third Affiliated Hospital of Sun Yat-Sen University

Professional Affiliations

Executive Council Member of Guangdong Anti-cancer Association

Vice Director of Medical Oncology Branch of Guangdong Medical Association

Committee Member of Medical Oncology Branch of Guangdong Medical Association

Leader of Tumor Biomarker Group of Medical Oncology Branch of Guangdong Medical Association

Standing Committee Member of Medical Oncology Specialist Branch of Guangdong Medical Doctor Association

Council Member of China Southwest Oncology Group

Committee Member of Chemotherapy Branch of Guangdong Anti-cancer Association

Standing Committee Member of Lymphoma Branch of Guangdong Anti-cancer Association

Chairman of Committee of the Targeted Therapy of Guangzhou Anti-cancer Association

Vice Director of Chemotherapy Committee Branch of Guangzhou Anti-cancer Association

Research Interests

Carcinogenesis of Hepatocellular Carcinoma

Carcinogenesis of Malignant Lymphoma

Palliative Therapy of Advance Cancer

Clinical Outcomes Analyses

His work focused on Carcinogenesis of Hepatocellular Carcinoma and Carcinogenesis of Malignant Lymphoma. He has published 21 SCI papers in journals such as Lancet Oncology, Nature Review of Clinical Oncology, Leukemia & Lymphoma ,Plos One，WJG，Nature Review of Clinical Oncology, Lancet Oncology, Tumor biology，Medical oncology，Leukemia & Lymphoma, Pathol Oncol Res, Annals of Oncology and etc. He has had continuous research funds support from Key Projects of Natural Science Foundation of China (NSFC), from University-industry Cooperation Projects of Education Ministry of Guangdong Province and from Science and Technology Plan Projectsof Guangdong Province.

Education and Experience

Training

·Internal Medicine Department of the Third Affiliated Hospital of Sun Yat-Sen University (Sep 1987-June 1990)

Residency

·Hematology Department of theThird Affiliated Hospital of Sun Yat-Sen University (June 1990-Oct 1992)

Attending Physician

·Hematology Department of theThird Affiliated Hospital of Sun Yat-Sen University (Oct 1992-Nov 1997)

Associate Chief Physician

·Hematology Department of theThird Affiliated Hospital of Sun Yat-Sen University (Nov 1997-Dec 2003)

Chief Physician

·Hematology Department of theThird Affiliated Hospital of Sun Yat-Sen University (Dec 2003-June 2005)

·Oncology Department of theThird Affiliated Hospital of Sun Yat-Sen University (June 2005 up to now)

 Medical Specialty

Professor Wu carried out the first case of allogeneic bone marrow stem cells transplantation in Guangdong Province. He has rich clinical experience in applying allogeneic bone marrow stem cells transplantation in treating acute leukemia.

In June 2005, he established Oncology Department. He has clinical experience for more than 30 years. He has rich clinical experience and deep attainments in chemotherapy, molecular target therapy and palliative therapy of malignant tumor.

Honors and Awards

Advanced Bethune-like Doctor of Guangdong Health System 1995

Second Prize of Excellent Medical Outcomes of Medical College of Sun Yat-Sen University 1997

Publications

1.Li X, Xing YF, Lin Qu, Wan XB, Wu XY*. The treatment of severe hepatitis B virus reactivation after chemotherapy. Nat Rev Clin Oncol.;9(6):350. 2012 May 1 (Corresponding author，2011 IF: 10.787 )

2.Wu XY*, Li X, Chen ZH, Dong M, Lin Q, Xing YF, Wei L, Wang TT, Chen J, Wen JY, Lin ZX, Wan XB, Ruan DY, Ma XK. An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: A pilot study. Tumour Biol. 2012 Dec 27. [Epub ahead of print] (Corresponding author，2011 IF: 2.143)

3.Dong M, Wan XB, Yuan ZY, Wei L, Fan XJ, Wang TT, Lv YC, Li X, Chen ZH, Chen J, Lin Q, Wen JY, Ma XK, Liu Q, Wu XY*. Low Expression of Beclin 1 and Elevated Expression of HIF-1α Refine Distant Metastasis Risk and Predict Poor Prognosis of ER-positive, HER2-n egative Breast Cancer. Med Oncol. 30(1):355.2013 Mar. (Corresponding author，2011 IF: 2.140)

4.Wu XY*, Chen J, Cao QH, Dong M, Lin Q, Fan XJ, Xia Q, Chen ZH, Liu Q, Wan XB. Beclin 1 activation enhances chemosensitivity and predicts a favorable outcome for primary duodenal adenocarcinoma. Tumour Biol. 2012 Dec 7. [Epub ahead of print] (Corresponding author，2011 IF: 2.143)

5.Wan XB, Fan XJ, Huang PY, Dong D, Zhang Y, Chen MY, Xiang J, Xu J, Li u L, Zhou WH, Lv YC, Wu XY, Hong MH*, Liu Q*. Aurora-A activation, correlated with hypoxia-inducible factor-1 α , promotes radiochemoresistance and predicts poor outcome for nasopharyngeal carcinoma. Cancer Sci.103(8):1586-94. 2012 Aug. ( 2011IF: 3.325)

6. Liu JJ, Hu T, Wu XY, Wang CZ, Xu Y, Zhang Y, Xiao RZ, Lin DJ *, Huang RW, Liu Q. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone--induced apoptosis in leukemia k562 cells and its mechanisms of action. Int J Toxicol. 28(2):123-31. 2009 Mar-Apr. (2008 IF: 1.267)

7.Wan XB, Zhao Y, Fan XJ, Cai HM, Zhang Y, Chen MY, Xu J, Wu XY, Li HB, Zeng YX, Hong MH*,Liu Q*. Molecular Prognostic Prediction for Locally Advanced Nasopharyngeal Carcinoma by Support Vector Machine Integrated Approach. PLoS One.7(3):e31989. 2012 ( 2011IF:4.092 )

8.Li X, Dong M, Lin Q, Chen ZH, Ma XK, Xing YF, Wan XB, Wen JY, Wei L, Chen J, Wu XY*. Comparison of current staging systems for advanced hepatocellular carcinoma not amendable to locoregional therapy as inclusion criteria for clinical trials. Asia Pac J Clin Oncol. 2012 Dec 27. [Epub ahead of print] ( Corresponding author，2011 IF: 0.585)

9.Li X, Lin Q, Dong M, Wen JY, Wei L, Ma XK, Chen ZH, Wu XY* . Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Leuk Lymphoma. 51(9):1678-85. 2010 Sep. ( Corresponding author，2010 IF: 2.397）

10.Zhong F, Zhang S, Shao CK, Yang J, Wu XY* . Arsenic trioxide inhibits cholangiocarcinoma cell growth and induces apoptosis. Pathol Oncol Res. 16(3):413-20. 2010 Sep. （Corresponding author，2009 IF: 1.152）

11.Wan XB, Fan XJ, Chen MY, Xiang J, Huang PY, Guo L, Wu XY, Xu J, Long ZJ, Zhao Y, Zhou WH, Mai HQ, Liu Q, Hong MH*. Elevated Beclin 1 expression is correlated with HIF-1alpha in predicting poor prognosis of nasopharyngeal carcinoma. Autophagy. 6(3):395-404. 2010. ( 2009 IF: 5.479）

12.Liu JJ* , Guo YW, Fang ZG, Si XN, Wu XY* , Liu PQ, Lin DJ, Xiao RZ, Xu Y, Wang CZ, Li XD, He Y, Huang RW. Activation of peroxisome proliferator-activated receptor-gamma induces apoptosis on acute promyelocytic leukemia cells via downregulation of XIAP. Int J Mol Med. 24(5):623-32. 2009 Nov. (Corresponding author， 2008 IF: 1.880)

Contact

Oncology Department,theThird Affiliated Hospital of Sun Yat-Sen University

600 Tianhe Road,Tianhe District, Guangzhou, China. 510630

Phone: +86-20-85252212

E-mail: wuxiangy@mail.sysu.edu.cn

             18922102979@163.com